1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Therapeutic Class Report Overview - Hemophilia

Therapeutic Class Report Overview - Hemophilia

  • February 2013
  • -
  • MP Advisors
  • -
  • 47 pages

Summary

Table of Contents

Hemophilia is an inherited (X-linked recessive trait), lifelong bleeding disorder that prevents blood from clotting due to insufficient or lack of adequate amount of clotting factors – Factor VIII (FVIII) and Factor IX (proteins in blood that control bleeding). Plasma-derived FVIII and FIX proteins were used in the 70’s for treating these disorders but transmission of contaminating viruses reduced its use. In 1999, recombinant FVIIIs and FIX, free of viral, animal, or human proteins became the standard of care (SoC). However, frequent injections used for prophylaxis resulted in development of antibodies (called inhibitors – acquired hemophilia or neutralizing abs) to FVIII or FIX. The presence of inhibitors complicated treatment of hemophilia A and B- ~30% in hemophilia A and up to 3 to 5% in hemophilia B pts. The high cost of treatment, frequent dosing, and infusion related adverse events are other concerns.

To address these limitations, companies are developing next generation clotting factors which are more potent – Short Acting or Long Acting Recombinant Factors. These potentially could result in fewer injections, reduce the inhibitor level, and improve compliance. Several of these pipeline products are now poised for approval and launch in the next two-three years. At present, Baxter, Bayer/ CSL, Pfizer, Novo Nordisk dominate the current ~$10b hemophilia market. In this report, we have analyzed the clinical efficacy, safety, and commercial prospects of the late-stage products in development and expect the long acting products that have best clinical and safety data to lead by offering patients better Cost per Quality Adjusted Life Year (QALY).

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2016

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • December 2016
  • by Global Markets Direct

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease ...

Acute Lung Injury - Pipeline Review, H2 2016

Acute Lung Injury - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • December 2016
  • by Global Markets Direct

Acute Lung Injury - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Acute Lung Injury – Pipeline Review, H2 2016, provides an overview ...

Sepsis - Pipeline Review, H1 2017

Sepsis - Pipeline Review, H1 2017

  • $ 2000
  • Company report
  • February 2017
  • by Global Markets Direct

Sepsis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sepsis – Pipeline Review, H1 2017, provides an overview of the Sepsis (Infectious ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.